The latest industry happenings, all in one place.
Paul Drake
Signant Health announced that it has appointed Paul Drake, PhD, as Chief Compliance and Security Officer.
Clinical SCORE announced the appointment of Samantha Daugherty to the position of Vice President, Director of Operations.
Adaptive Clinical Systems has hired Temitope Keyes as VP of Business Development.
Crosstree has announced that Gordon Ryerson is returning to the firm to launch the company’s newest service: Strategic Value Creation.
Raremark announced additions to its executive team. Neil Rotherham, Tim Davis, and Jeremy Edwards have been appointed Chairman, Chief Executive
Officer and Chief Commercial Officer, respectively.
Temitope Keyes
Karadeniz Technical University Farabi Hospital has joined Clinerion’s Patient Network Explorer platform.
Trialbee announced that it has experienced triple year over year growth.
AiCure announced their revenue has grownby over 65% from the prior year.
ERT announced an ERT record: 75% of the compounds approved by U.S. FDA in 2019 were developed using one or more of ERT’s eClinical solutions during the drug development process.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.